Fig. 4: Cotadutide enhances hepatic insulin-stimulated signaling pathways in DIO mice. | Nature Communications

Fig. 4: Cotadutide enhances hepatic insulin-stimulated signaling pathways in DIO mice.

From: GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice

Fig. 4

Schematic depicting proteomic and phosphoproteomics changes in the insulin signaling pathway based on the experimental design described in Fig. 3A including comparisons (detailed further in figure key) between the following groups: vehicle + PBS (VP), vehicle + insulin (VI), cotadutide + PBS (CP), and cotadutide +  insulin (CI). Due to space limitations, selected phosphosites are shown. *Indicates data derived from immunoblot or separate proteomic studies as noted in text. The full list of phosphosites is detailed in Supplementary Data. Created in BioRender. Kajani, S. (2025) https://BioRender.com/t41v037 (A). Immunoblot of phosphorylated AKT at serine 473 from the groups described in Fig. 3A compared to total AKT (B). n = 4 mice per group. In (A, B), increased or decreased proteomic or phosphoproteomics changes based on p < 0.05 and abundance ratio <0.76 or >1.315, or p < 0.01 and abundance ratio <0.76 or >1.315, respectively. The in-built one-way ANOVA test in Proteome Discover (PD) was used to generate p values. Source data are provided as a Source Data file.

Back to article page